scholarly journals Prophylactic radiotherapy for procedure tract metastases in mesothelioma

2017 ◽  
Vol 23 (4) ◽  
pp. 357-364 ◽  
Author(s):  
David T. Arnold ◽  
Amelia O. Clive
2016 ◽  
Vol 17 (10) ◽  
pp. e418 ◽  
Author(s):  
David Landau ◽  
Eric Lim

2019 ◽  
Vol 37 (14) ◽  
pp. 1200-1208 ◽  
Author(s):  
Neil Bayman ◽  
Wiebke Appel ◽  
Linda Ashcroft ◽  
David R. Baldwin ◽  
Andrew Bates ◽  
...  

PURPOSE Prophylactic irradiation to the chest wall after diagnostic or therapeutic procedures in patients with malignant pleural mesothelioma (MPM) has been a widespread practice across Europe, although the efficacy of this treatment is uncertain. In this study, we aimed to determine the efficacy of prophylactic radiotherapy in reducing the incidence of chest wall metastases (CWM) after a procedure in MPM. METHODS After undergoing a chest wall procedure, patients with MPM were randomly assigned to receive prophylactic radiotherapy (within 42 days of the procedure) or no radiotherapy. Open thoracotomies, needle biopsies, and indwelling pleural catheters were excluded. Prophylactic radiotherapy was delivered at a dose of 21 Gy in three fractions over three consecutive working days, using a single electron field adapted to maximize coverage of the tract from skin surface to pleura. The primary outcome was the incidence of CWM within 6 months from random assignment, assessed in the intention-to-treat population. Stratification factors included epithelioid histology and intention to give chemotherapy. RESULTS Between July 30, 2012, and December 12, 2015, 375 patients were recruited from 54 centers and randomly assigned to receive prophylactic radiotherapy (n = 186) or no prophylactic radiotherapy (n = 189). Participants were well matched at baseline. No significant difference was seen in the incidence of CWM at 6 months between the prophylactic radiotherapy and no radiotherapy groups (no. [%]: 6 [3.2] v 10 [5.3], respectively; odds ratio, 0.60; 95% CI, 0.17 to 1.86; P = .44). Skin toxicity was the most common radiotherapy-related adverse event in the prophylactic radiotherapy group, with 96 patients (51.6%) receiving grade 1; 19 (10.2%), grade 2; and 1 (0.5%) grade 3 radiation dermatitis (Common Terminology Criteria for Adverse Events, version 4.0). CONCLUSION There is no role for the routine use of prophylactic irradiation to chest wall procedure sites in patients with MPM.


1989 ◽  
Vol 5 (3) ◽  
pp. 415-422 ◽  
Author(s):  
Joan Houghton ◽  
Michael Baum

The Cancer Research Campaign (CRC) Trial demonstrates a decreased incidence of local recurrence for patients randomized to prophylactic radiotherapy following mastectomy. Irradiated patients alive after 5 years, however, have a small increased risk of dying from causes other than breast cancer. How to estimate the cost-benefit of such therapy is discussed.


2006 ◽  
Vol 43 (1) ◽  
pp. 36-41 ◽  
Author(s):  
Ichiro Kawahara ◽  
Kenta Masui ◽  
Nobutaka Horie ◽  
Takayuki Matsuo ◽  
Naoki Kitagawa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document